The Development of INT131 as a Selective PPAR𝜸 Modulator: Approach to a Safer Insulin Sensitizer

Figure 9

Preclinical LOAEL for PPARγ full agonists follows a steep time dependence. The lowest observable adverse effect level (LOAEL) at various exposure times in mouse, rat, and monkey is depicted for aggregate data for the class and expressed as multiple of clinical exposure level. Data from [21].